News · 26 weeks23-60%
2025-12-282026-06-21
Mix1890d
- SEC Filings9(50%)
- Other6(33%)
- Earnings2(11%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 CongressNEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. BALLI-01 clinical trial evaluating la
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALLNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The granting of RMAT designation reflects the FDA's recognition of the potential for lasme-cel to address the unmet medical need fac
- ANALYSTBarclays initiated coverage on Cellectis with a new price targetBarclays initiated coverage of Cellectis with a rating of Overweight and set a new price target of $9.00
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis' Annual Shareholders General Meeting to be Held on June 25, 2026NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice of meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/ About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual CongressNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association (EHA) annual congress, on June 11-14, 2026, in Stockholm, Sweden. Lasme-cel – Oral Presentation The abstract reporting the full Phase 1 dataset from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T, in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL), has been
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Reports Financial Results for the First Quarter 2026Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 dataset expected in Q4 2026 Innovation Preclinical data on TALE-based epigenetic editing, a non-DNA cutting approach, to be presented at ASGCT Servier (through Allogene): Interim pivotal data reported from the ALPHA3 trial of cema-cel (n=24) 58.3% of patients in the cema-cel arm achieved MRD negativity versus 16.7% in the observation armFavorable safety profile: no cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse EventsStudy accrual expected to be comple
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Report First Quarter Financial Results on May 11, 2026NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2026 ending March 31, 2026 on Monday, May 11, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com About Cellectis Cellectis
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual MeetingNEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based epigenetic editing approach, that does not cut or permanently modify the DNA sequence, making it a potentially safer alternative for genome editing, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 11-15, in Boston (MA). The data will be presented in a poster: Title: TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T PlatformNEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today highlights the interim futility analysis announced by Allogene Therapeutics, Inc. ("Allogene") from Allogene's sponsored pivotal ALPHA3 trial evaluating cema-cel in first-line consolidation for large B-cell lymphoma (LBCL). Cema-cel is a product candidate licensed to Servier under the License, Development and Commercialization Agreement signed by and between les Laboratoires Servier and Institut de Recherches Internationales Servier ("Servier") and Cellectis (the "Serv
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2025 results and an update on business activities. Details for the call are
- ANALYSTJefferies resumed coverage on Cellectis with a new price targetJefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Announces 2026 Strategy and CatalystsNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026. "2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel." said André Choulika, Ph.D., Chief Executive Officer of Cellectis. "As we enter 2026, we remain fully committed to executing our pivotal Phase 2 BALLI-01 trial for lasme-cel in ALL, with interim data expected in Q4, presen
- PRAllogene Therapeutics Reports Favorable Result for Servier in Arbitration with CellectisArbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the f
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
CLLS FAQ
7 questionsWhat does Cellectis S.A. do?
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma...Where does CLLS stock trade?
Cellectis S.A. (CLLS) is listed on NASDAQ.What sector and industry is CLLS in?
Cellectis S.A. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cellectis S.A. go public?
Cellectis S.A. (CLLS) completed its IPO in 2015.What are analysts saying about CLLS?
Cellectis S.A. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $900.00 price target on 2026-05-28. Recent price targets range from $600.00 to $2000.00.What companies are similar to CLLS?
Notable peers in the same industry include ALLO (Allogene Therapeutics Inc.), PSTX (Poseida Therapeutics Inc.), CLXT (Calyxt Inc.). Compare CLLS side-by-side with any of them on Quantisnow.How can I track CLLS on Quantisnow?
Quantisnow aggregates Cellectis S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLLS to receive live email and push alerts on every new disclosure.